Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 5/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24690187 | 1.00 | LRRK2 (0.42) | LRRK2MAPTERN1NCOA1NCOA3 | |
| SCHEMBL30955842 | 0.84 | RXRA (0.44) | ALDH1A1CSNK2A1 | |
| SCHEMBL24690305 | 0.84 | RXRA (0.44) | ALDH1A1CSNK2A1 | |
| SCHEMBL4029897 | 0.81 | LRRK2 (0.44) | LRRK2MAPTERN1NCOA1NCOA3 | |
| SCHEMBL30019935 | 0.78 | ERN1 (0.37) | LRRK2ERN1NCOA1NCOA3CLK4 | |
| SCHEMBL24690188 | 0.78 | ERN1 (0.37) | LRRK2ERN1NCOA1NCOA3CLK4 | |
| SCHEMBL2513525 | 0.77 | EGFR (0.47) | LMNAALDH1A1TSHRHSD17B10 | |
| SCHEMBL4029655 | 0.77 | MAPT (0.50) | LRRK2MAPTNCOA1NCOA3CLK4 | |
| SCHEMBL6160731 | 0.76 | USP2 (0.34) | MAPTUSP2ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL4026769 | 0.75 | MAPT (0.36) | LRRK2MAPTNCOA1NCOA3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254093-A1 | GPR35 Agonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| EP-4326708-A1 | GPR35 AGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254093-A1 | GPR35 Agonist Compounds | GPR35, GPR119, GPR68 | LRRK2 724/4885MAPT 944/4885ERN1 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.